Year-To-Date and Q3 2018 Results

8 November 2018 07:00 BST

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come. Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in Emerging Markets.

These new medicines are showing great promise, including Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma. We’re also continuing to replenish our early-stage pipeline as we bring our innovative medicines to patients around the world. ”



Year-To-Date and Q3 2018 Results announcement
Year-To-Date and Q3 2018 Results Presentation
Year-To-Date and Q3 2018 Clinical Trials appendix

Adrian Kemp
Company Secretary
AstraZeneca PLC


  • Corporate and financial